To gain some mechanistic insight into the observed PG2 pharmacological activities, we examined its effect on the cancer-complicit component of the inflammatory cascade, the nuclear factor kappa protein, beta subunit (NF-κB) [30], pro-angiogenic marker CD31, and pro-inflammatory macrophage marker CD11b [31]. Here, PECAM1 is linked to cancer.